Tag: Biotechnology

. OpenAI has developed revolutionary ChatGPT technology to help employees manage multiple jobs efficiently and undetected. Ben, a Canadian marketer, recently told how he used the new GPT-4 version of the AI technology to compose his cover letter and secure a second job. Employees are increasingly using AI to boost their careers and productivity, but employers must take the right measures to protect their employees. OpenAI's mission is to ensure that AI remains beneficial to humanity.

OpenAI, a San Francisco-based research firm and non-profit focusing on developing artificial general intelligence (AGI), appointed Mira Murati as CTO in 2018. She leads the development and launch of innovative AI models like ChatGPT, the image-generator DALL-E, and GPT-4. Murati envisions a safe AGI system and advocates cooperation amongst industry players to achieve common safety standards. She believes in redirecting AI systems to engage more with reality, guardrailing good behavior and involving governmental regulations to protect users and developers.

Beating death is now a possibility, with Sam Altman, the CEO of OpenAI introducing his life-extension program – Retro Biosciences. Enjoy up to 10 years as healthy humans, as Altman's ground-breaking fusion power and biotechnology projects revolutionize the healthcare industry. With additional investments into Helion Energy, Longevity Vision Fund, Tempus, Elysium Health, and Valo Health, aged 37 Altman is a visionary!

Excelra, a global leader in life science data & digital solutions, is now even more powerful after acquiring BISC Global, a renowned bioinformatics/data analytics consulting firm. This strategic move unifies expertise in AI, ML, & omics data analysis, allowing Excelra to offer integrated services across life science and drive future innovation.

This new study findings may become a “game changer” in the efforts to identify people with Parkinson's disease. UTHealth's McGovern Medical School researchers, headed by Claudio Soto, PhD and funded by The Michael J. Fox Foundation, developed a patented technology employing misfolded alpha-synuclein to detect the disease accurately. The technology has been used to survey 1,123 participants from around the world, giving a diagnosis accuracy of up to 98.6%. This breakthrough offers a greater chance of earlier detection and better therapeutic treatments.